|
||
Amodis Dosage |
||
Generic name: Amodis 250mg
Dosage form: tablet, film coated
See also:
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
One-day treatment – two grams of Amodis, given either as a single dose or in two divided doses of one gram each, given in the same day.
Seven-day course of treatment – 250 mg three times daily for seven consecutive days. There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen.
The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other.
Pregnant patients should not be treated during the first trimester. In pregnant patients for whom alternative treatment has been inadequate, the one-day course of therapy should not be used, as it results in higher serum levels which can reach the fetal circulation.
When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment.
Treatment should be individualized as it is for the female.
For acute intestinal amebiasis (acute amebic dysentery): 750 mg orally three times daily for 5 to 10 days.
For amebic liver abscess: 500 mg or 750 mg orally three times daily for 5 to 10 days.
Pediatric patients: 35 to 50 mg/kg/24 hours, divided into three doses, orally for 10 days.
In the treatment of most serious anaerobic infections, intravenous Amodis is usually administered initially.
The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period.
The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.
For patients with severe hepatic impairment (Child-Pugh C), the dose of Amodis should be reduced by 50%.
Hemodialysis removes significant amounts of Amodis and its metabolites from systemic circulation. The clearance of Amodis will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of Amodis cannot be separated from the hemodialysis session, supplementation of Amodis dosage following the hemodialysis session should be considered, depending on the patient's clinical situation.
Tell your doctor about all other medicines you use, especially:
cimetidine (Tagamet);
seizure medication such as phenytoin (Dilantin) or phenobarbital (Luminal, Solfoton);
a blood thinner such as warfarin (Coumadin, Jantoven);
lithium (Lithobid, Eskalith, others); or
disulfiram (Antabuse).
This list is not complete and other drugs may interact with Amodis. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Psychotic reactions have been reported in alcoholic patients who are using Amodis and disulfiram concurrently. Amodis should not be given to patients who have taken disulfiram within the last two weeks.
Abdominal cramps, nausea, vomiting, headaches, and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following Amodis therapy.
Amodis has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. When Amodis is prescribed for patients on this type of anticoagulant therapy, prothrombin time and INR should be carefully monitored.
In patients stabilized on relatively high doses of lithium, short-term Amodis therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning Amodis to detect any increase that may precede clinical symptoms of lithium intoxication.
Amodis has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity. Amodis should not be administered concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to Amodis are available, and concomitant administration with busulfan is medically needed, frequent monitoring of busulfan plasma concentration should be performed and the busulfan dose should be adjusted accordingly.
The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may prolong the half-life and decrease plasma clearance of Amodis.
The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of Amodis, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.
Amodis may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide adenine dinucleotide (NAD- NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and Amodis (322 nm) at pH 7.
Users | % | ||
---|---|---|---|
3 times in a day | 8 | 50.0% | |
Twice in a day | 5 | 31.2% | |
Once in a day | 2 | 12.5% | |
4 times in a day | 1 | 6.2% |
Users | % | ||
---|---|---|---|
201-500mg | 6 | 60.0% | |
51-100mg | 1 | 10.0% | |
501mg-1g | 1 | 10.0% | |
101-200mg | 1 | 10.0% | |
11-50mg | 1 | 10.0% |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|